Immune-based therapies are approved for use in patients with no actionable molecular tumor alterations (Figure 1) but are not indicated for front-line use in EGFR-mutant NSCLC patients that are the subject of this review (Lee C. K. et al., 2017). The gene discussed is EGFR; the disease is neoplasm.